Literature DB >> 33456463

Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration.

Guangzhen Wu1, Yingkun Xu2, Chenglin Han2, Zilong Wang2, Jiayi Li3, Qifei Wang1, Xiangyu Che1.   

Abstract

PURPOSE: To construct a survival model for predicting the prognosis of patients with kidney renal clear cell carcinoma (KIRC) based on gene expression related to immune response regulation.
MATERIALS AND METHODS: KIRC mRNA sequencing data and patient clinical data were downloaded from the TCGA database. The pathways and genes involved in the regulation of the immune response were identified from the GSEA database. A single factor Cox analysis was used to determine the association of mRNA in relation to patient prognosis (P < 0.05). The prognostic risk model was further established using the LASSO regression curve. The survival prognosis model was constructed, and the sensitivity and specificity of the model were evaluated using the ROC curve.
RESULTS: Compared with normal kidney tissues, there were 28 dysregulated mRNA expressions in KIRC tissues (P < 0.05). Univariate Cox regression analysis revealed that 12 mRNAs were related to the prognosis of patients with renal cell carcinoma. The LASSO regression curve drew a risk signature consisting of six genes: TRAF6, FYN, IKBKG, LAT2, C2, IL4, EREG, TRAF2, and IL12A. The five-year ROC area analysis (AUC) showed that the model has good sensitivity and specificity (AUC >0.712).
CONCLUSION: We constructed a risk prediction model based on the regulated immune response-related genes, which can effectively predict the survival of patients with KIRC.
Copyright © 2020 Guangzhen Wu et al.

Entities:  

Year:  2020        PMID: 33456463      PMCID: PMC7787716          DOI: 10.1155/2020/6657013

Source DB:  PubMed          Journal:  J Oncol        ISSN: 1687-8450            Impact factor:   4.375


  44 in total

1.  TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells.

Authors:  Yefei Rong; Dansong Wang; Wenchuan Wu; Dayong Jin; Tiantao Kuang; Xiaolin Ni; Lei Zhang; Wenhui Lou
Journal:  Med Oncol       Date:  2014-09-25       Impact factor: 3.064

2.  A New Prognostic Risk Model Based on PPAR Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma.

Authors:  Yingkun Xu; Xiunan Li; Yuqing Han; Zilong Wang; Chenglin Han; Ningke Ruan; Jianyi Li; Xiao Yu; Qinghua Xia; Guangzhen Wu
Journal:  PPAR Res       Date:  2020-09-22       Impact factor: 4.964

3.  FYN promotes breast cancer progression through epithelial-mesenchymal transition.

Authors:  Ye-Gong Xie; Yue Yu; Li-Kun Hou; Xin Wang; Bin Zhang; Xu-Chen Cao
Journal:  Oncol Rep       Date:  2016-06-22       Impact factor: 3.906

4.  Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro
Journal:  J Clin Oncol       Date:  2007-08-01       Impact factor: 44.544

Review 5.  Oncogenic EGFR signaling networks in glioma.

Authors:  Paul H Huang; Alexander M Xu; Forest M White
Journal:  Sci Signal       Date:  2009-09-08       Impact factor: 8.192

6.  Epiregulin expression by Ets-1 and ERK signaling pathway in Ki-ras-transformed cells.

Authors:  Min-Chul Cho; Hee-Sook Choi; Sojung Lee; Bo Yeon Kim; Mira Jung; Sue Nie Park; Do-Young Yoon
Journal:  Biochem Biophys Res Commun       Date:  2008-10-21       Impact factor: 3.575

7.  Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy.

Authors:  D Elias; H Vever; A-V Lænkholm; M F Gjerstorff; C W Yde; A E Lykkesfeldt; H J Ditzel
Journal:  Oncogene       Date:  2014-06-02       Impact factor: 9.867

8.  Traf6 inhibitor boosts antitumor immunity by impeding regulatory T cell migration in Hepa1-6 tumor model.

Authors:  Xiao Wu; Rong Xue; Hao Peng; Xiaojie Gan; Xu Lu; Wei Yan; Yizhu Tian; Xuhao Ni; Hongbin Shen; Feng Cheng; Xuehao Wang; Xiaoming Wang; Ling Lu
Journal:  Int Immunopharmacol       Date:  2019-10-26       Impact factor: 4.932

Review 9.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

10.  Post-translational regulation of COX2 activity by FYN in prostate cancer cells.

Authors:  Anna Alexanian; Bradley Miller; Marla Chesnik; Shama Mirza; Andrey Sorokin
Journal:  Oncotarget       Date:  2014-06-30
View more
  2 in total

1.  Development and Validation of a Novel PPAR Signaling Pathway-Related Predictive Model to Predict Prognosis in Breast Cancer.

Authors:  Yingkun Xu; Dan Shu; Meiying Shen; Qiulin Wu; Yang Peng; Li Liu; Zhenrong Tang; Shun Gao; Yuan Wang; Shengchun Liu
Journal:  J Immunol Res       Date:  2022-06-02       Impact factor: 4.493

2.  Construction and Validation of Angiogenesis-Related Prognostic Risk Signature to Facilitate Survival Prediction and Biomarker Excavation of Breast Cancer Patients.

Authors:  Yingkun Xu; Yang Peng; Meiying Shen; Li Liu; Jinwei Lei; Shun Gao; Yuan Wang; Ailin Lan; Han Li; Shengchun Liu
Journal:  J Oncol       Date:  2022-04-20       Impact factor: 4.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.